Drugs.com - Clinical Trials

Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to Placebo

Ingelheim, Germany, May 19, 2025 - Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential inhibitor...

May 20, 2025 - 01:30
 0
Global Phase III Trials Demonstrate That Nerandomilast Slowed Lung Function Decline in IPF and PPF, with Similar Discontinuation Rates to Placebo
Ingelheim, Germany, May 19, 2025 - Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential inhibitor...
Read More

Tags:

Previous Article

Le site de classification des ingrédients de parfumerie Scentree se transforme

Next Article

IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain ...

Related Posts

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission

Aldeyra Therapeutics Achieves Primary Endpoint in Phase...

May 12, 2025  0

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

Biogen’s Investigational Tau-Targeting Therapy BIIB080 ...

May 12, 2025  0

ESSENCE Phase 3 Trial of Semaglutide Showed Significant Improvements at 72 Weeks in Adults with MASH, Published in NEJM

ESSENCE Phase 3 Trial of Semaglutide Showed Significant...

May 12, 2025  0